povorcitinib

Phase 3Small molecule

Incyte

povorcitinib is one of 46 small molecule programs targeting Hidradenitis Suppurativa (HS). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hidradenitis Suppurativa (HS)Recruiting

Moderate to Severe AsthmaActive, not recruiting

Non-Segmental VitiligoActive, not recruiting

VitiligoActive, not recruiting

Prurigo NodularisRecruiting

Hidradenitis Suppurativa (HS)Phase 3

Recruiting

Moderate to Severe AsthmaPhase 2

Active, not recruiting

Non-Segmental VitiligoPhase 3

Active, not recruiting

VitiligoPhase 3

Active, not recruiting

Prurigo NodularisPhase 3

Recruiting

Competition

Competitive Landscape

36 competitors in Vitiligo

#DrugCompanyPhaseTrials

Jakafi

Incyte

Approved

8 2

Trexall

Jazz Pharmaceuticals

Approved

2 3

Cosentyx

Novartis

Approved

1 4

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 5

Decadron

AAspen Global Incorporated

Approved

2 6

Asmanex

PPerrigo Company

Approved

1 7

Elidel

BBausch Health Americas, Inc.

Approved

—8

Rapamune

PPrism Pharmaceuticals

Adrucil

Rinvoq

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Hidradenitis Suppurativa (HS)

NCT06212999

Q1 2027

Phase 3Active, not recruiting

Non-Segmental Vitiligo

NCT06113445

Phase 3Active, not recruiting

Vitiligo

NCT06113471

Q2 2027

Phase 3Recruiting

Prurigo Nodularis

NCT06516952

Phase 3Recruiting

Prurigo Nodularis

NCT06516965

Q3 2027

Phase 2Active, not recruiting

Moderate to Severe Asthma

NCT05851443

Clinical

Trials by Indication[1]

Hidradenitis Suppurativa (HS)3 trials

A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Recruiting· Incyte logo

Incyte·Phase 3·NCT06855498·600 enrolled

A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting· Incyte logo

Incyte·Phase 3·NCT06212999·617 enrolled

A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa

Recruiting· Incyte logo

Incyte·Phase 2·NCT07213973·40 enrolled

Hidradenitis Suppurativa2 trials

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Completed· Incyte logo

Incyte·Phase 3·NCT05620823·608 enrolled

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed· Incyte logo

Incyte·Phase 3·NCT05620836·619 enrolled

Prurigo Nodularis2 trials

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

Recruiting· Incyte logo

Incyte·Phase 3·NCT06516952·330 enrolled

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

Recruiting· Incyte logo

Incyte·Phase 3·NCT06516965·330 enrolled

Vitiligo1 trial

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

Active, not recruiting· Incyte logo

Incyte·Phase 3·NCT06113471·450 enrolled

Chronic Spontaneous Urticaria1 trial

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

Completed· Incyte logo

Incyte·Phase 2·NCT05936567·136 enrolled

6 more indications

Oral1 trial

A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants

Completed· Incyte logo

Incyte·Phase 1·NCT06505265·18 enrolled

Interaction1 trial

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

Completed· Incyte logo

Incyte·Phase 1·NCT06380205·24 enrolled

Metformin1 trial

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

Completed· Incyte logo

Incyte·Phase 1·NCT06416800·71 enrolled

ART1 trial

A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

Completed· Incyte logo

Incyte·Phase 1·NCT06441318·128 enrolled

Non-segmental Vitiligo1 trial

A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo

Active, not recruiting· Incyte logo

Incyte·Phase 3·NCT06113445·467 enrolled

Moderate to Severe Asthma1 trial

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Active, not recruiting· Incyte logo

Incyte·Phase 2·NCT05851443·247 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for povorcitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — povorcitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for povorcitinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Incyte

povorcitinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Hidradenitis Suppurativa (HS)3 trials

Hidradenitis Suppurativa2 trials

Prurigo Nodularis2 trials

Vitiligo1 trial

Chronic Spontaneous Urticaria1 trial

Oral1 trial

Interaction1 trial

Metformin1 trial

ART1 trial

Non-segmental Vitiligo1 trial

Moderate to Severe Asthma1 trial

References

Drug Info

Quick Facts

Related News